08:45 AM EDT, 10/27/2025 (MT Newswires) -- Revolution Medicines ( RVMD ) said Monday that its daraxonrasib has received Orphan Drug Designation from the US Food and Drug Administration for the treatment of pancreatic cancer.

The company said daraxonrasib, its RAS(ON) multi-selective inhibitor, is being studied in a phase 3 trial in patients who have second-line metastatic pancreatic ductal adenocarcinoma, or PDAC.

Revolution Medicines ( RVMD ) added there are also plans for phase 3 studies for first-line treatment in patients with metastatic PDAC and for adjuvant treatment in patients with resectable PDAC.

The company's shares were up over 3% in recent premarket activity.